Effects of various antiplatelet drugs on ex vivo platelet activation induced by equine herpesvirus type 1.

This research study investigated the effects of standard antiplatelet drugs on platelet activation due to equine herpesvirus type 1 (EHV-1) in horses. Despite administering a variety of antiplatelet medications, none were found to significantly impact EHV-I-induced platelet activation in affected horses.

Objective and Methodology

The aim of this study was to examine the effects of antiplatelet treatment in horses affected by EHV-1. To do this, researchers conducted a double-blind, placebo-controlled crossover study with 11 healthy horses.

Four different antiplatelet drugs – theophylline, pentoxifylline, clopidogrel bisulfate, and acetylsalicylic acid – were administered orally to the horses over a period of five days, with doses spaced 12 or 24 hours apart according to the specific medication. A three-week washout period separated each treatment round to prevent drug interactions.

Blood samples were collected before and after each treatment round, and a platelet-rich plasma was prepared from the samples. These platelets were then exposed to two strains of EHV-1. Platelet activation was assessed by measuring the percentages of P-selectin-positive platelets and platelet-derived microparticles (PDMPs) with flow cytometry.

Results

After examining the results, the researchers found that none of the administered antiplatelet drugs had a significant effect on EHV-I-induced platelet activation, as measured by the percentages of P-selectin-positive platelets and PDMPs.

Among the treatments, only clopidogrel significantly inhibited platelet aggregation in response to ADP in platelet-rich plasma samples obtained after the treatment session.

Conclusions and Clinical Relevance

The conclusions drawn from this research suggest that standard antiplatelet medications do not impact the activation of platelets induced by EHV-1 in horses, as assessed via α-granule exteriorization or microvesiculation and release of PDMPs ex vivo.

This holds significant importance for equine healthcare, as it suggests these treatments may not prevent in vivo platelet activation caused directly by EHV-1. This finding could contribute to our understanding and improvement of treatment approaches for diseases associated with EHV-1-induced platelet activation in horses.